Ian Scheil, a patient advocate and founder of iaNSAID, has raised concerns about the exploitation of the 340B Drug Pricing Program by hospitals for profit. In a letter to the editor published in the Rochester Beacon, Scheil claimed that hospitals are leveraging the program to generate revenue while patients continue to pay full price for medications.
“In 2016, my life changed forever,” said Scheil, Patient Advocate; Founder. “That’s no longer happening. With the help of corporate middlemen, hospitals have figured out how to exploit the 340B program by buying drugs at massive discounts and reselling them at incredible markups. Instead of reducing the cost to patients, hospitals are charging patients like me full price. Patients deserve better. We need greater transparency, accountability, and affordability, not a system that allows hospitals and out-of-state corporate middlemen to profit off programs meant for patient care.”
Reports from New York have highlighted issues with the 340B Drug Pricing Program, suggesting that hospitals and corporate intermediaries are profiting at the expense of patient care. According to PhRMA, which cited an investigation by The New York Times, some hospitals have partnered with for-profit contractors to purchase drugs at significant discounts and then resell them to insurers at full price. This practice reportedly generates substantial revenue while providing minimal charity care, leading critics to argue that it undermines the program’s mission to assist low-income patients.
Rochester Regional Health, which oversees Rochester General Hospital, reported approximately $3.2 billion in revenue in 2022. ProPublica’s Nonprofit Explorer revealed that executive compensation within the system exceeded $3.6 million in one year, with top executives like Eugene Morley earning over $728,000. These figures underscore the financial magnitude of the hospital system and invite scrutiny regarding its compensation practices.
In New York State, only about 24 percent of 340B contract pharmacies are situated in medically underserved areas; most are located in wealthier or commercially attractive neighborhoods. According to data summarized on Wikipedia, this uneven distribution has led to criticism that financial benefits from 340B disproportionately favor affluent areas rather than directly aiding vulnerable patients. This issue reflects broader national discussions on program equity.
Scheil is based in Rochester, New York, and has a professional background in advocacy and leadership roles as per his LinkedIn profile. He founded iaNSAID to address disparities in access to nonsteroidal anti-inflammatory drugs (NSAIDs) and aims to enhance transparency in prescription drug pricing.
iaNSAID is a patient advocacy organization dedicated to improving transparency and affordability concerning NSAID pricing. The group’s official website states its mission is to educate patients, promote accountability in pharmaceutical pricing, and engage policymakers so that drug discounts and rebates benefit consumers directly. It advocates for reforms aimed at reducing out-of-pocket costs while amplifying the patient voice in health care policy discussions.
